Written by the Nuvirox Research Team
Key points
- Stem cell exhaustion is one of the classical hallmarks of aging, but the name is misleading — in blood, the stem cell pool often grows with age while each cell functions worse.
- In humans, this shows up as clonal hematopoiesis: by later life, a large share of blood production traces back to a small number of mutated stem cell clones.
- That pattern carries measurable risk — an 11-fold hazard ratio for haematologic cancer and roughly doubled risk of coronary heart disease — and no supplement or clinic has been shown to reverse it.
Short answer: your body does not run out of stem cells so much as end up relying on worse ones. Stem cell exhaustion sits on every list of the hallmarks of aging, and the intuitive picture — a reservoir slowly draining — turns out to be wrong for most tissues. In blood, the number of stem cells often increases with age while their regenerative capacity falls. What actually collapses is diversity: in young people thousands of stem cell clones contribute to blood production simultaneously, and in older people a handful of clones do most of the work. That shift is measurable in human blood, and it predicts real clinical outcomes.
What does stem cell exhaustion actually mean?
Adult stem cells are the maintenance crew for tissues that need constant replacement — blood, gut lining, skin, and to a lesser extent muscle. They sit mostly quiescent and activate on demand. Aging degrades this system through at least three routes that operate together: intrinsic damage inside the cell, changes in the surrounding niche that supports it, and inflammatory signalling that distorts the instructions the cell receives.
The result differs by tissue, which is why the single label is unhelpful. Skeletal muscle satellite cells — the stem cells responsible for muscle repair — do decline in number with age, and become less responsive to the signals that should activate them. That contributes directly to the pattern described in our piece on why fast-twitch muscle goes first. Bone marrow behaves almost oppositely: phenotypic hematopoietic stem cells increase in frequency with age while losing function per cell.
Two tissues, two patterns. The word 'exhaustion' describes the muscle case reasonably well and the blood case poorly.
What human studies actually show
Clonal hematopoiesis is the clearest human evidence, and it was found by accident. In 2014, three independent groups sequencing blood DNA for other reasons noticed the same thing: healthy older adults commonly carry expanded populations of blood cells sharing a somatic mutation, most often in DNMT3A, TET2, or ASXL1. Jaiswal and colleagues, Genovese and colleagues, and Xie and colleagues all published in the same window. The condition is rare in the young and becomes common with age.
The associated risks are substantial. In the Jaiswal analysis, the presence of a somatic mutation was associated with a hazard ratio of 11.1 for haematologic cancer, 1.4 for all-cause mortality, 2.0 for incident coronary heart disease, and 2.6 for ischaemic stroke. The cardiovascular associations were unexpected — nobody was looking for a link between blood stem cell mutations and heart disease — and a follow-up analysis in 2017 examined that connection directly.
Clonal diversity collapses with age. Deep sequencing of peripheral blood in humans shows that in young individuals thousands of stem cells contribute to blood production at any given time. In aged individuals there is a dramatic collapse, such that the majority of blood is sustained by only a few clones. The factors driving that collapse are not well understood, and a 2025 review in Cell Stem Cell was direct about that gap.
Some of what looks like exhaustion is actually the wrong cells winning. This is the counterintuitive finding worth sitting with. Certain mutations — in PPM1D and SRCAP, for instance — make stem cells more resistant to environmental insults and less prone to apoptosis. Those cells are not healthier in any functional sense; they are simply harder to kill, so they accumulate. In mice, the age-related decline in blood production has been attributed to dysfunctional stem cells outcompeting less resilient but functional ones. Aging the tissue is partly a selection problem, not only a damage problem.
Hazard ratios associated with clonal hematopoiesis in the 2014 Jaiswal analysis. The cardiovascular associations were an unexpected finding, not a hypothesis the study was designed to test.
Why does the niche matter as much as the cell?
Stem cells do not operate in isolation. In bone marrow, mesenchymal stromal cells support hematopoiesis, and with age these increasingly give rise to adipocytes instead — producing the fatty marrow characteristic of older adults and degrading the structural environment stem cells depend on. Inflammatory signalling in the niche changes too, with IL-6 and TGF-β1 identified as regulators of hematopoietic ageing.
This connects stem cell aging to the chronic low-grade inflammation covered in our piece on inflammaging, and to senescent cells, which secrete inflammatory factors into surrounding tissue. These hallmarks are not independent; they feed each other, which is part of why single-target interventions have been disappointing.
What nothing currently does
There is no intervention shown to reverse stem cell exhaustion in humans. Not a supplement, not a peptide, not an intravenous infusion. This deserves emphasis because it is an area with unusually aggressive commercial activity.
Clonal hematopoiesis itself is not currently something to screen for outside research settings. It is common, most people who have it never develop a haematologic malignancy, and there is no established intervention that changes its course. Incidental detection on a genetic test is a reason to discuss it with a haematologist, not a reason to act.
What does have evidence
The interventions with support are indirect and unglamorous. Resistance training measurably improves satellite cell function and muscle regenerative capacity in older adults — the single best-evidenced intervention in this space. Adequate protein intake supports the same system. Cardiovascular risk factor management matters more given the clonal hematopoiesis link to coronary disease and stroke. Not smoking matters for the obvious reason that somatic mutation rate is a driver of the whole process.
For context on how this fits the broader picture, see our overview of the twelve hallmarks of aging. And the mechanism most closely intertwined with stem cell dysfunction — damage to mitochondrial DNA — is covered in our piece on whether mtDNA mutations actually drive aging. If you want a practical, free measure that reflects how well your repair systems are keeping up, walking speed is a surprisingly informative one.
Frequently asked questions
Do I have clonal hematopoiesis?
If you are over 70, there is a meaningful chance you do — prevalence rises steeply with age. It is not detected on a standard blood count and requires targeted sequencing. Since there is no established intervention, most experts do not recommend testing outside research or specific clinical contexts.
Can exercise regenerate stem cells?
Exercise does not create new stem cells, but resistance training improves the function and responsiveness of muscle satellite cells in older adults, which is the practical thing that matters. That is the best-evidenced intervention affecting stem cell function in humans.
Do NAD+ precursors affect stem cells?
There is preclinical work suggesting NAD+ availability influences stem cell function, particularly in muscle, and mitochondrial quality control in stem cells depends on NAD+-linked pathways. Human trials have not measured stem cell function as an endpoint, so the honest position is that this is a plausible mechanism without human confirmation.
Is stem cell exhaustion why wounds heal slower with age?
It is one contributor among several. Slower healing also reflects reduced blood flow, changes in collagen deposition, altered immune signalling, and comorbidities like diabetes. Attributing it to a single hallmark oversimplifies a multifactorial process.
Are the CHIP mutations inherited?
No. These are somatic mutations acquired during life in blood stem cells, not germline mutations you inherit or pass on. They accumulate as a function of time and cell division, which is why prevalence climbs with age.
From Nuvirox
Why we formulated NAD+ Restore
Stem cell function depends on cellular energy and repair capacity, and NAD+ sits at the centre of both — it is the coenzyme required for energy metabolism and for the enzymes involved in DNA repair signalling. NAD+ Restore delivers 500 mg of nicotinamide riboside, one of the two most-researched NAD+ precursors, within the dose range used in published human trials.
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials.
- 150 mg trans-resveratrol (Japanese Knotweed) and 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support.
- 10 mg galactomannans from fenugreek — to support absorption.
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
The bottom line
Stem cell exhaustion is a real hallmark of aging with a misleading name. In blood, the pool frequently expands while function falls and clonal diversity collapses, so that a few mutated clones come to dominate production — a pattern that carries an 11-fold hazard ratio for haematologic cancer and roughly doubled cardiovascular risk. In muscle, the pool genuinely shrinks. What unites both is that no available intervention reverses the process in humans, and the clinics claiming otherwise are selling something the evidence does not support. Resistance training, adequate protein, cardiovascular risk management, and not smoking are the interventions with actual support.
References
- Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–2498. DOI: 10.1056/NEJMoa1408617.
- Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477–2487. DOI: 10.1056/NEJMoa1409405.
- Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12):1472–1478. DOI: 10.1038/nm.3733.
- Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366(6465):eaan4673. DOI: 10.1126/science.aan4673.
- Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–121.
- Hallmarks of stem cell aging. Cell Stem Cell. 2025. Article PII: S1934-5909(25)00226-7.
- Goodell MA, Rando TA. Stem cells and healthy aging. Science. 2015;350(6265):1199–1204. DOI: 10.1126/science.aab3388.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.